Q-omics provides the consensus-scored TRMT2B profile across patient tissues and cancer cell-line models. TRMT2B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TRMT2B is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, TRMT2B RNA expression shows 19,971 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where TRMT2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRMT2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRMT2B survival associations across molecular data types. TRMT2B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRMT2B RNA expression–survival associations across cancer types. High TRMT2B expression shows unfavorable associations in LGG, KICH and BRCA, but favorable associations in KIRC, SCLC and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TRMT2B RNA expression.
This table summarizes TRMT2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TRMT2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRMT2B shows lower tumor expression in THCA and higher tumor expression in BLCA, COAD, LIHC, BRCA and LUAD. The THCA box plot shows higher TRMT2B RNA expression in normal versus tumor tissue (log2 FC = −0.958, t-test p < 0.001).
This table shows molecular features associated with TRMT2B in patient tissues and cancer cell lines. In patient samples, TRMT2B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRMT2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
